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Abstract
Schizophrenia is a devastating psychiatric illness with high heritability. Brain structure and 
function differ, on average, between schizophrenia cases and healthy individuals. As common 
genetic associations are emerging for both schizophrenia and brain imaging phenotypes, we can 
now use genome-wide data to investigate genetic overlap. Here we integrated results from 
common variant studies of schizophrenia (33,636 cases, 43,008 controls) and volumes of several 
(mainly subcortical) brain structures (11,840 subjects). We did not find evidence of genetic overlap 
between schizophrenia risk and subcortical volume measures either at the level of common variant 
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genetic architecture or for single genetic markers. The current study provides proof-of-concept 
(albeit based on a limited set of structural brain measures), and defines a roadmap for future 
studies investigating the genetic covariance between structural/functional brain phenotypes and 
risk for psychiatric disorders.
Keywords
schizophrenia; MRI; brain imaging; genetics; GWAS; meta-analysis; endophenotype
Introduction
Schizophrenia is a devastating, highly heritable psychiatric disorder that affects 
approximately 1% of the population. 1 Despite marked recent successes in identifying 
genetic risk factors and pathways involved in schizophrenia, 1-4 the neurobiology of 
schizophrenia remains poorly understood.
Many differences in brain function and structure have been reported in cases with 
schizophrenia compared with controls, although there is considerable inter-individual 
heterogeneity. Of specific relevance to this study, a recent meta-analysis found that 
schizophrenia cases had smaller hippocampus, amygdala, thalamus, nucleus accumbens, and 
intracranial volumes along with larger pallidum and lateral ventricle volumes.5,6 
Hippocampal and lateral ventricle volumes were influenced by antipsychotic medication 
use.
5
 In addition, mean hippocampal volume is smaller in high-risk individuals and in 
unaffected first-degree relatives of schizophrenia cases. 7,8
Structural brain measurements, such as those from magnetic resonance imaging (MRI), 
typically have high reproducibility and low measurement error and can be highly 
heritable. 9,10 Increasingly large studies of brain morphometry are being performed, and are 
being used to evaluate the effects of common and rare genetic contributions on brain 
structure. 
9
,
11
With genome-wide association results available from large samples for schizophrenia and 
for MRI-based brain phenotypes, we can now use genomic approaches to evaluate the 
genetic link between disease risk and such brain measures. Findings of covariation would 
help us develop new hypotheses about the structures involved in the primary disease process 
of schizophrenia. In this proof-of-concept study, we created a roadmap for the analysis of 
genetic covariation using a battery of complementary methods. We evaluated the overlap of 
common genetic variation at the high level of genetic architecture as well as of individual 
genetic variants. We also evaluated common genetic variant effect sizes on neuroimaging 
phenotypes and schizophrenia. The data we analyzed are from large mega-analyses by the 
PGC (Psychiatric Genomics Consortium) for schizophrenia 3 and meta-analyses from the 
ENIGMA consortium (Enhancing NeuroImaging Genetics through Meta-Analysis) for eight 
MRI volumetric measures (amygdala, caudate nucleus, hippocampus, nucleus accumbens, 
pallidum, putamen, thalamus, and intracranial volume (ICV)). 9 Our results suggest that 
common genetic variation predisposing to schizophrenia does not show evidence of overlap 
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with common genetic variation influencing these eight brain structure volumes. Genetic 
effect sizes did not differ significantly for neuroimaging and schizophrenia phenotypes.
Results
We analyzed genome-wide association data for schizophrenia (33,636 cases and 43,008 
controls) and eight structural MRI brain measures (11,840 individuals). Sample 
characteristics are presented in Supplementary Table 1. These data were used for a 
comprehensive set of comparisons of common variant genetic sharing between 
schizophrenia and brain volumetric measures.
Comparisons of common variant genetic architectures
Linkage disequilibrium score regression (LDSR)—Using GWA summary statistics 
(excluding the extended MHC region), we used LDSR 12 to estimate the heritability of 
schizophrenia due to common SNPs at 25.5% (SE=1.1%) along with eight brain volumetric 
measures (Table 1). The SNP-based heritability estimates for the MRI measures ranged from 
11% (nucleus accumbens) to 30% (putamen). The heritability for amygdala volume was 
non-significant in this sample. The genetic correlations of MRI volumetric measures with 
schizophrenia were all non-significant (Table 1). These negative findings stand in contrast to 
the relatively high common-variant correlations of schizophrenia with bipolar disorder and 
major depressive disorder. 13,14
Genetic predisposition scores—In the genetic “risk” score approach, 15 we considered 
the ENIGMA GWA results as “training” sets in order to compute common variant genetic 
predisposition to (for instance) greater ICV for each schizophrenia case and control. We then 
compared the mean polygenic predisposition score in cases to that in controls. None of the 
correlations was significant after correction for eight comparisons (Figure 1 and Table 2). 
The strongest effect (for hippocampal volume) was almost entirely driven by one SNP 
(rs2268894), 9 but only three SNPs met the p-value threshold of 1×10−6 for inclusion in this 
analysis. These null results are in contrast to the robust evidence for common variant genetic 
correlations between schizophrenia and other psychiatric disorders. 16
Rank-rank hypergeometric overlap test (RRHO) 17—We quantified overlap between 
pairs of GWA results ranked by their association statistics using RRHO based on 172,652 
SNPs. The overlap of rank-ordered lists of genetic variants influencing any of the brain MRI 
volumes and those conferring risk for schizophrenia was not statistically significant (Figure 
2). The overlap between genetic contributions to putamen and caudate nucleus volumes was 
used as a positive control; the overlap between genetic contributions to hippocampal volume 
and the presumably unrelated trait of thumb whorl structure 18 was used as a negative 
control. The latter comparison showed similar overlap to that of brain structure and 
schizophrenia.
Sign tests
We compared the pattern of GWA results by checking whether the signs of the regression 
coefficients 3 were consistently in the same direction between the top associations for 
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schizophrenia and those for the MRI volumetric measures. None of the sign tests showed 
consistent directions of effect (Table 3).
Analysis of single genetic variants
Genome-wide significant associations—We evaluated the 128 genome-wide 
significant schizophrenia index SNPs 3 for association with brain volumes. 9 One association 
survived correction for 876 comparisons: rs2909457*A (chr2:162,845,855, intergenic 
between SLC4A10 and DPP4) was associated with decreased hippocampal volume 
(P=1.2×10−6, effect size=−23 mm3 per allele) and decreased risk for schizophrenia (odds 
ratio=0.94, P=4.6×10−8). However, this finding was in the opposite direction of expectations 
given previous observations of smaller hippocampal volumes in cases relative to controls 
(Supplementary Table 2). 6 Starting with the eight SNPs previously found associated with 
the brain volumes, 9 no significant associations with schizophrenia were observed 
(Supplementary Table 2).
SNP meta-analyses—We also performed GWA meta-analyses of the schizophrenia and 
brain structure results. The Manhattan plots for these analyses are shown in Supplementary 
Figures 1-8. In Supplementary Table 3, the genome-wide significant findings are given. In 
most instances, the results were entirely driven by the association with schizophrenia.
Conjunction analysis—To identify individual SNPs that influence risk for both 
schizophrenia and brain structure, we implemented a conjunction test. 19 No SNP showed 
genome-wide significant association with both schizophrenia and brain structure, although 
several loci were detected at sub-threshold levels (Supplementary Figure 9).
Comparison of genetic effect sizes for clinical and brain volume measures
Some investigators have suggested that common genetic variants underlying continuous 
brain imaging endophenotypes may have larger effect sizes than those for neuropsychiatric 
disorders (e.g., schizophrenia). 20-22 To test this hypothesis, we compared the maximum 
effect sizes from replicated genetic associations for each trait. For comparability across 
quantitative or binary traits, effect sizes were assessed as percent of variance explained (for 
MRI volumes) or percent of variance explained on the liability scale (for schizophrenia). 23 
As shown in Supplementary Figure 10, individual common variants had only a small 
influence on either brain structure or schizophrenia. Effect sizes for individual SNPs were 
similar for both brain structure and schizophrenia, and of the same order as those observed 
for anthropometric traits such as height. 24
Discussion
In this proof-of-concept study, we evaluated the relationship between common genetic 
variants implicated in schizophrenia and those associated with subcortical brain volumes and 
ICV. The sample sizes were the largest yet applied to these questions. With a comprehensive 
set of analyses, we did not find evidence for notable genetic correlations, either at a high 
level (i.e., common variant genetic architecture) or for single genetic markers. Our findings 
do not support the hypothesis that these subcortical brain volume measures and ICV are 
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causally associated with schizophrenia risk. Similarly, we did not find evidence that 
common SNPs have pleiotropic effects on these MRI volumes and schizophrenia. Our 
results suggest alternative hypotheses that require consideration and refutation – that the 
volumetric differences observed in schizophrenia cases may be epiphenomena unrelated to 
its primary genetic causes, a result of prenatal environment, or result from reverse 
causation. 25 Finally, the effect sizes of SNPs implicated in schizophrenia and those 
associated with brain volumes were broadly similar.
We studied a limited set of brain MRI measures. Our study should be considered a proof-of-
concept for evaluating genetic covariation rather than decisively addressing the full range of 
hypotheses pertaining to the genetic overlap of brain imaging measures with 
neuropsychiatric disease risk. We provide a rigorous roadmap for more definitive and larger 
future studies. Full elucidation of the brain correlates of schizophrenia will require a fuller 
set of structural and functional imaging measures (perhaps at the voxel level) along with 
evaluation of common and rare genetic variation.
The null findings of this study should be interpreted in light of several qualifiers. First, 
several brain regions that are not expected a priori to overlap with schizophrenia were 
included for completeness (e.g., caudate and putamen volumes are uncorrelated with 
schizophrenia, 5,6 and amygdala volume did not have SNP-heritability different from zero in 
our study). Second, other neuroimaging phenotypes could be more informative for 
schizophrenia (e.g., cortical thickness, ventricular volume, diffusion tensor imaging, or 
functional activity). 26,27 Indeed, genetic variants associated with disease may influence 
distinct cell types within circumscribed neural circuits that may not be captured by MRI. 
Third, the ENIGMA MRI protocol served to harmonize images obtained from different 
scanners and protocols. While we have shown this performs well, genetic signal might have 
been lessened. Fourth, in this study of adults, we may not have observed the brain regions at 
the most appropriate time for identifying genetic overlap with schizophrenia, given that the 
volumes of most subcortical brain structures plateau in late adolescence to early adulthood. 
While schizophrenia is widely believed to be a neurodevelopmental disorder, 28 its onset 
generally follows the period of greatest growth for these structures. Fifth, relatively small 
genetic correlations between schizophrenia and these brain volumes may have been masked 
by combining datasets in a meta-analytic framework (e.g., heterogeneous sample 
characteristics such as age, sex, and technical noise resulting from different MRI scanners or 
acquisition sequences may remain). It is conceivable that this resulted in the lower than 
expected SNP-heritability for some of these measures. Mega-analysis could be an important 
way to improve control for heterogeneity. Sixth, we evaluated only common genetic 
variation. Although common genetic variation explains far more of the risk for 
schizophrenia than rare copy number variation or rare deleterious exonic variation, 2 rare 
genetic effects on brain structure could be salient for some cases of schizophrenia. Finally, 
the sample sizes and statistical power of the schizophrenia and neuroimaging data sets 
differed. The PGC has attained a sample size sufficient to detect many common loci of small 
effect, whereas ENIGMA is earlier in the discovery arc. 29
Brain volume heritability estimates from genome-wide data obtained using LDSR 14 were 
lower than observed in previous studies. 30 This was expected for the subcortical regions, as 
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those were corrected for ICV. For ICV, a likely source of difference with previous studies is 
the removal of the extended MHC region from our analysis.
Although we found no evidence for genetic correlation between subcortical volumes and 
schizophrenia, we also investigated whether effect sizes of genetic variants are larger for 
brain measures than for schizophrenia. This point has been debated with respect to 
“endophenotype” studies, which attempt to identify quantifiable brain measures or other 
biomarkers thought to be intermediate between genotype and the liability to a disorder. 31-33 
An endophenotype that lies on a causal pathway to a clinical disorder could increase power 
for genetic studies. Prior studies addressed this hypothesis in far smaller samples. We 
compared SNP effect sizes for the top findings for schizophrenia with those for subcortical 
volumes (hippocampus, putamen, caudate) and ICV. The results of this analysis showed 
similar effect sizes. Importantly, the endophenotype concept is unlikely to be sufficiently 
addressed in these analyses given the reasons noted above.
In conclusion, this paper presents a roadmap for comprehensive evaluation of genetic 
covariation between neuropsychiatric disease liability and brain imaging measures. The 
current analysis was limited to a small number of brain volume phenotypes, and no evidence 
of genetic overlap was identified. More extensive brain-wide and genome-wide analyses 
may help in the mechanistic dissection of genetic risk for disease.
Online Methods
A supplementary methods checklist is available. The data used for the analyses described 
here are available to researchers. The ENIGMA data can be obtained from http://
enigma.ini.usc.edu/enigma-vis. The PGC data can be downloaded from http://
www.med.unc.edu/pgc/downloads.
PGC schizophrenia
We mega-analyzed individual genotype data from 46 European-ancestry schizophrenia 
GWAS datasets (full details in reference 3). Briefly, quality control and imputation were 
performed by the PGC Statistical Analysis Group for each dataset separately. Genotype 
imputation was with the pre-phasing/imputation stepwise approach implemented in 
IMPUTE2/SHAPEIT (chunk size of 3 Mb and default parameters) using the 1000 Genomes 
Project dataset (phase 1, August 2012, URLs). After imputation, we identified autosomal 
SNPs with high imputation accuracy across all samples. For robust relatedness testing and 
population structure analysis, we evaluated a subset of SNPs following LD-pruning (r2 > 
0.02) and frequency filtering (MAF > 0.05). For association testing, we evaluated the 46 
datasets separately using an additive logistic regression model including ancestry principal 
components as covariates, and then conducted a meta-analysis of the 52 sets of results using 
an inverse-weighted fixed effects model. After excluding subjects who were also in 
ENIGMA (N=458, see below), 33,636 cases and 43,008 controls were used for calculations 
(Supplementary Table 1).
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ENIGMA, sample with brain volume measures and assessment of endophenotype
The data analyzed here are from the ENIGMA analysis of eight MRI volumetric measures 
(full details in reference 9). MRI brain scans and genome-wide genotype data were available 
for 11,840 subjects from 22 cohorts (Supplementary Table 1). Only cohorts without 
schizophrenia cases and controls overlapping with the PGC schizophrenia samples were 
included. Participants clustered with subjects of known European ancestry as verified by 
multidimensional scaling (MDS) analysis. Genomic data were imputed to a reference panel 
(1000 Genomes, v3 phase1) comprising only European samples and with monomorphic 
SNPs removed. Imputation was performed at each site using MaCH for phasing and 
minimac for imputation. 34 Only SNPs with an imputation score of RSQ > 0.5 and minor 
allele counts > 10 within each site were included. Tests of association were conducted 
separately for eight MRI volumetric phenotypes (nucleus accumbens, amygdala, caudate 
nucleus, hippocampus, pallidum, putamen, thalamus, and ICV) with the following covariates 
in a multiple linear regression framework: age, age2, sex, 4 MDS components (to account for 
population structure), ICV (for subcortical brain phenotypes), and diagnosis (when 
applicable). The GWA statistics from each of the 22 sites were combined using a fixed-effect 
inverse variance-weighted meta-analysis as implemented in METAL. 35
Removal of duplicated individuals
Subject overlap between all PGC and ENIGMA cohorts was evaluated using a checksum 
algorithm in order to ensure the robustness of our results given that some analyses were 
sensitive to the presence of duplicate individuals. For each individual, ten checksum 
numbers were created based on ten batches of 50 SNP genotypes and compared between 
individuals from both consortia. Based on these comparisons and a general exclusion of 
cohorts containing schizophrenia cases, 1,517 individuals were removed from ENIGMA and 
458 subjects were removed from the PGC.
Linkage disequilibrium score regression (LDSR)
For LDSR, each dataset underwent additional filtering. Only markers overlapping with 
HapMap Project Phase 3 SNPs and passing the following filters were included: INFO score 
> 0.9 (where available), study missingness of 0, and MAF >1%. Indels and strand-
ambiguous SNPs were removed. To remove a potential source of bias, all SNPs in the 
extended MHC region (chr6:25-35 Mb) were removed from all datasets. The schizophrenia 
analysis included only results from European studies were used (LDSR requires LD data 
from a comparable sample). For the ENIGMA amygdala results, the mean Χ2 was too low 
(1.0051) to reliably estimate heritability using LDSR.
The analysis was conducted using a two-step procedure with the LD-scoring analysis 
package. 12,14 An unconstrained regression was run to estimate the regression intercepts for 
each phenotype, followed by an analysis with regression intercepts constrained to those 
estimated in the first step and the covariance intercept defined as zero (note that we took 
steps to exclude overlapping samples). Standard errors were estimated using a block 
jackknife procedure and used to calculate P-values.
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Genetic predisposition analyses
To investigate the combined impact of ENIGMA association results on case-control status in 
the PGC schizophrenia data, we performed a series or genetic predisposition score analyses. 
For each ENIGMA volumetric phenotypes, we excluded SNPs with MAF <2%, indels, and 
SNPs in the extended MHC region (chr6:25-34 Mb). We then “clumped” the data, 
discarding variants within 500 kb of and in r2 ≥ 0.1 with another more significant marker. 
We performed genetic predisposition score prediction of target subgroups as originally 
described 15 for several P-value thresholds (5×10−8, 1×10−6, 1×10−4, 0.001, 0.01, 0.05, 0.1, 
0.2, 0.5, 1.0), multiplying the effect size of the ENIGMA phenotype of each variant by the 
imputation probability for the risk allele in each individual. The resulting values were 
summed so that each individual had a genetic predisposition score for further analyses. Two 
outcome variables are reported in Table 2: the significance of the case-control score 
difference analyzed by logistic regression (including ancestry-based principal components 
and a study indicator as covariates) and the proportion of variance explained (Nagelkerke's 
R2) computed by comparison of a full model (covariates + polygenic risk scores) score to a 
reduced model (covariates only). Note that these R2 estimates are biased due to recruitment 
of the case-control studies and as the numbers of cases and controls do not reflect the 
underlying risk of disease in the population.
Rank-rank-hypergeometric overlap test (RRHO)
RRHO 17 tests the hypothesis that ordering of two lists (LD-pruned GWAS results for 
schizophrenia versus a brain structure phenotype) by the strength of their association is 
arbitrary. The number of independent SNPs in common between the two ordered lists is 
evaluated at specified step sizes. Two lists that show similar ordering of SNPs demonstrate a 
global pattern of similarity of associations. Independent SNPs were selected based on the 
1000 Genomes European dataset for 200 SNP windows shifted at five SNP intervals using 
an r2 threshold of 0.25. SNPs found in both PGC and ENIGMA data with MAF ≥ 0.01 were 
retained (172,652 SNPs). The SNPs were then ordered by the –log10(p-value) of association 
multiplied by the effect size. A two-sided RRHO test that allowed testing for either over- or 
under-enrichment was used with a step-size of 3000 SNPs.
Finger whorl data used as control in conjunction analysis
A GWAS of a dermatoglyphic trait (presence of a whorl on the left thumb), collected as part 
of an ongoing study at the Queensland Institute of Medical Research, 18 was used to provide 
a negative control for the RRHO test. Briefly, rolled ink prints were collected on archival 
quality paper, and fingerprint patterns were manually coded. Complete data from 3,314 
participants (twins and their family members) were available. Genotypes were imputed to 
the 1000 Genomes Project reference (phase 1 version 3). GWAS was conducted using 
Merlin-offline to account for relatedness and zygosity.
Lookup of top GWAS SNP findings
Evidence for an effect of the reported 128 independent schizophrenia-associated SNPs on 
subcortical brain volumes and ICV was studied through a look-up of results. rs115329265 
was not available in the ENIGMA data and was replaced by a SNP in moderate LD 
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(chr6:28305863R; r2=0.64); rs77149735 was not available in ENIGMA and could not be 
replaced by a SNP in LD. Three chrX SNPs (rs1378559, rs5937157, and rs12845396) were 
excluded, because chrX data were not available from ENIGMA. Effects of the eight 
independent SNPs associated with brain volumes reported by ENIGMA on schizophrenia 
risk were studied through a look-up of results in the PGC data.
Multiple comparison correction was performed by estimating the effective number of 
independent tests (Meff). This method considers the correlation structure (Supplementary 
Table 4) between brain measures and calculates the Meff based on the observed eigenvalue 
variance of the different brain volume measures using matSpD (see URLs). The p-value for 
significance was 0.05 divided by the sum of (a) Meff times the number of SNPs included in 
the lookup from PGC to ENIGMA (n=124), and (b) the number of SNPs included in the 
lookup from ENIGMA to PGC (n=8). Eight brain volumes resulted in seven independent 
tests, and only SNPs with a P < 5.7×10−5 were considered significant.
SNP sign test in the top GWAS findings
To investigate a potential accumulation of same or opposite direction effects of SNPs 
between PGC schizophrenia and ENIGMA, we counted the number of same direction 
effects for the top-findings from the schizophrenia dataset (94 LD-independent genome-
wide significant SNPs, 231 with P < 1×10−6) in the different brain structure datasets and 
tested the significance of the result in a binomial test (n=14 tests for 7 effective ENIGMA 
phenotypes and 2 P-value thresholds).
Conjunction analysis
To determine whether a particular SNP is linked to both brain structure and risk for 
schizophrenia, a conjunction analysis was used. 19 This analysis makes inference on the 
alternative hypothesis that both null hypotheses are false. This is in distinction to a 
traditional meta-analysis method which infers on an alternative hypothesis that one or more 
null hypotheses are false. A conjunction analysis is calculated as: Pconj = max(Pbrain, 
Pcase-control), where Pbrain is the significance of the SNP associated to brain structure and 
Pcase-control is the significance of the SNP association to schizophrenia. As conjunction tests 
can be very conservative, an adjustment to this test 36 based on the estimated fraction of 
false nulls was used here with modifications (P'conj). Over 7.5 million SNPs found in both 
the ENIGMA and PGC datasets with MAF ≥ 0.01 were evaluated.
A conjunction null hypothesis is the union of the individual null hypotheses, producing a 
‘composite null hypothesis’. In standard testing situations a “point null hypothesis” is used, 
meaning that there is exactly one configuration of the unknown parameters of interest that 
corresponds to the null. For example, “no gene-brain association, no case-control 
association” is a point null hypothesis. A composite null has multiple configurations. For 
example, both of these configurations fall into the conjunction null hypothesis: “true gene-
brain association, no case-control association”; “no gene-brain association; true case-control 
association”. A valid conjunction test has to control false positive risk over all possible 
configurations in the conjunction null. Put another way, a conjunction test has to be 
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calibrated for the worst possible configuration of true signals, and as a result can be quite 
conservative when the true state of the model is not one of the extreme cases.
The method of Deng et al. 36 attempts to reduce the conservativeness of the conjunction 
procedure in the multiple testing setting. The authors propose a method that estimates 
prevalence of null hypotheses in each of the individual tests being combined. With this 
information, a “relaxed” test can be constructed that is less conservative. However, a crucial 
equation in that paper is in error. The equation below provides the estimator for the 
proportion of false null hypothesis for each of the two tests to be combined. The expression 
is based on the method of Storey 37, who posed it as an estimate of the proportion of true 
null hypotheses. Deng et al. 36 apparently inverted the result incorrectly; the correct 
expression is:
In our analyses, the λ parameter in the equation above was set to 0.25.
SNP meta-analysis
We combined the association P-values of SNPs associated with schizophrenia with SNPs 
associated with the seven subcortical brain volumes and ICV from ENIGMA. Using 
METAL, 35 we conducted a sample size-weighted meta-analysis for schizophrenia (effective 
sample size 71,715) and ENIGMA (variable sample sizes per SNP ranging from 
8,000-11,000). SNPs were excluded if they were not present in both datasets and for MAF < 
1% (per analysis). The total number of SNPs present in the eight meta-analyses ranged from 
7,847,762 to 7,945,194.
SNP effect size comparisons
SNP effect sizes were extracted from studies of brain structure (ENIGMA), 9 schizophrenia 
(PGC), 3 height (GIANT), 24 and educational attainment (EduYears). 38 The five highest 
effect size SNPs were selected for schizophrenia and height, all genome-wide significant 
SNPs were displayed for brain structure volumes and EduYears. Percent variance was 
calculated on the liability scale for schizophrenia for comparison with quantitative traits. 23 
For brain structures, height, and EduYears, percent variance explained was calculated as 
R2g|c/(1-R2c) = (t2/((n-k-1)+t2))*100, where the t-statistic is calculated as the ß-coefficient 
for a given SNP from the regression model (controlling for covariates) divided by the 
standard error of the ß-estimate, n is the total number of subjects, and k is the total number 
of covariates. 95% confidence intervals were calculated by transforming percent variance 
explained to a Z-statistic using Fisher's Z transformation, finding the 95% confidence 
intervals of the Z-statistic, and transforming this interval back into percent variance 
explained.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Summary
The authors defined a roadmap for the investigation of the genetic covariance between 
structural/functional brain phenotypes and risk for psychiatric disorders. Their proof-of-
concept study using the largest available common variant datasets for schizophrenia and 
volumes of several (mainly subcortical) brain structures did not find evidence of genetic 
overlap.
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Figure 1. 
Genetic predisposition score analyses examining the predictive capacity of ENIGMA brain 
volumetric results on schizophrenia case-control status using different P-value thresholds. X-
axis: (a) hippocampus, (b) ICV, (c) nucleus accumbens, (d) amygdala, (e) caudate nucleus, 
(f) pallidum, (g) putamen, (h) thalamus. Y-axis shows Nagelkerke's R2. Positive values 
indicate SNP effects for increasing brain structure volume and increased risk for 
schizophrenia. Negative values indicate SNP effects for decreasing brain structure volume in 
and increased risk for schizophrenia. Significance values are given in Table 2.
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Figure 2. 
Evaluating the genome-wide overlap between genetic influences on schizophrenia and 
subcortical volumes. (a) A cartoon describing the output map. (b-i) independent SNPs 
present in both ENIGMA and PGC schizophrenia results were selected independent of 
association to any phenotype (see on-line methods). Association results were ordered based 
on the significance of their association to the phenotype (–log10(P-value) multiplied by the 
sign of the effect), and statistical significance was evaluated using RRHO test. The same test 
for overlap was conducted with a (j) finger whorl phenotype, expected to have no overlap 
with brain structure genetics, and (k) the overlap between caudate and putamen volume, 
expected to have very strong overlap. Overlap in the rank-ordered lists between genetic 
variants influencing any of the eight brain phenotypes and those creating risk for 
schizophrenia was not statistically significant. The overlap between hippocampal volume 
and presence of a whorl on the left thumb was used as a negative control and showed similar 
levels of overlap to brain structure and schizophrenia.
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Table 1
SNP-heritability analyses for MRI brain volume and genetic correlations with schizophrenia*.
Brain region* N Heritability SE Genetic correlation with SCZ SE Z P
Intracranial volume 9,826 0.157 0.050 −0.010 0.072 −0.137 0.891
Caudate nucleus 11,624 0.260 0.043 −0.095 0.057 −1.674 0.094
Hippocampus 11,621 0.135 0.041 −0.147 0.081 −1.826 0.068
Nucleus accumbens 11,603 0.105 0.045 −0.094 0.090 −1.051 0.293
Pallidum 11,595 0.137 0.047 −0.038 0.069 −0.546 0.585
Putamen 11,598 0.303 0.052 0.013 0.052 0.256 0.798
Thalamus 11,646 0.118 0.041 −0.113 0.087 −1.298 0.194
*
amygdala heritability was too low to allow a valid analysis
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Table 2
Two outcome variables derived from genetic predisposition analysis.
Phenotype P- R2 AUC OR (95% CI)
Intracranial volume 0.247
−2.46×10−5 0.512 0.944 ( 0.877,1.016)
Caudate nucleus 0.033
−8.35×10−5 0.502 0.928 (0.864,0.997)
Hippocampus 0.010
−1.23×10−4 0.506 0.917 (0.853,0.986)
Nucleus accumbens 0.002
−1.74 ×10−4 0.500 0.928 (0.862,0.9996)
Pallidum 0.985 6.21 ×10−9 0.513 1.034 (0.963,1.111)
Putamen 0.607
−4.87×10−6 0.515 0.971 (0.891,1.059)
Thalamus 0.221
−2.75×10−5 0.510 0.959 (0.888,1.036)
Amygdala 0.806 1.11×10−6 0.509 1.021 (0.951,1.096)
P=significance uncorrected for multiple testing. R2=correlation (Nagelkerke) on the observed scale corrected for principal components. AUC=area 
under receiver operating characteristic curve. OR=odds ratio. CI=confidence interval
Nat Neurosci. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Franke et al. Page 43
Table 3
Sign tests of directional effects among 94 genome-wide significant associations with schizophrenia 
(P<5×10−8) and the top 231 associations (P<1×10−6).
Brain region P threshold N same direction Proportion P
Intracranial volume <5×10−8 49 0.52 0.379
Caudate nucleus <5×10−8 47 0.50 0.541
Hippocampus <5×10−8 46 0.49 0.621
Nucleus accumbens <5×10−8 48 0.51 0.459
Pallidum <5×10−8 51 0.54 0.235
Putamen <5×10−8 52 0.55 0.177
Thalamus <5×10−8 49 0.52 0.379
Amygdala <5×10−8 49 0.52 0.379
Intracranial volume <1×10−6 121 0.52 0.255
Caudate nucleus <1×10−6 113 0.49 0.653
Hippocampus <1×10−6 105 0.45 0.926
Nucleus accumbens <1×10−6 109 0.47 0.821
Pallidum <1×10−6 117 0.51 0.448
Putamen <1×10−6 115 0.50 0.552
Thalamus <1×10−6 115 0.50 0.552
Amygdala <1×10−6 109 0.47 0.821
The expected proportion under the null is 0.5.
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